Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Alexion Pharmaceuticals Inc

+ Add to Watchlist

ALXN:US

188.0500 USD 10.2700 5.78%

As of 20:10:00 ET on 01/29/2015.

Snapshot for Alexion Pharmaceuticals Inc (ALXN)

Open: 172.4000 Day's Range: 172.3500 - 189.0300 Volume: 3,015,202
Previous Close: 177.7800 52wk Range: 136.3700 - 203.3000 1-Yr Rtn: +18.47%

Stock Chart for ALXN

No chart data available.
  • ALXN:US 188.0500
  • 1D
  • 1M
  • 1Y
177.7800
Interactive ALXN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ALXN

Current P/E Ratio (ttm) 55.8071
Estimated P/E(12/2015) 31.7116
Relative P/E vs. SPX 3.1329
Earnings Per Share (USD) (ttm) 3.3696
Est. EPS (USD) (12/2015) 5.9300
Est. PEG Ratio 1.1790
Market Cap (M USD) 37,287.85
Shares Outstanding (M) 198.29
30 Day Average Volume 1,392,612
Price/Book (mrq) 11.2924
Price/Sale (ttm) 16.6786
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/24/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ALXN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ALXN

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.

Leonard Bell "Lenny"CEO/Treasurer/Co-FounderDavid L HallalChief Operating Officer
Vikas SinhaExec VP/CFOClare CarmichaelExec VP/Chief Human Resource Ofcr
More Company Profile & Key Executives for ALXN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil